Find policies, billing codes, payers, states, and providers
CPT 51720: Intravesical Instillation of Anticarcinogenic Agent
CPT code 51720 represents intravesical instillation of an anticarcinogenic agent into the bladder, a commonly used local therapy for bladder cancer. The procedure delivers medication directly into the bladder via a catheter, where the agent is retained for a specified dwell time before drainage. Intravesical therapy is an important component of bladder cancer management because it targets the urothelium while limiting systemic exposure.
Key national payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, United Healthcare, and Medicare. The summary highlights payer coverage considerations and common billing relationships for this service across outpatient settings.
Readers will find a concise overview of clinical context for intravesical anticarcinogenic instillation, typical sites of service such as ambulatory surgical centers and hospital outpatient departments, and related procedural codes used in bladder catheterization and bladder irrigation. The publication also provides benchmarking and reimbursement context across major payers, coding relationships to nearby CPT services, and common ICD-10 diagnoses that typically support medical necessity for this procedure. This information is intended to support coding accuracy, billing workflows, and payer discussions at a national level.
Customize your policy alerts
Sign up for cpt 51720 policy alerts
Get alerted when payer policies referencing 51720 are released or updated.
Monitor payer policy activity
Billing Code Overview
CPT code 51720 describes the intravesical instillation of an anticarcinogenic agent into the bladder via catheter, with the agent retained for a period before being drained. This procedure is a localized oncologic therapy aimed at treating bladder cancer by delivering medication directly to the bladder lining.
Service type: Intravesical chemotherapy/anticarcinogenic instillation
Typical site of service: Ambulatory surgical center or hospital outpatient department; may also be performed in an outpatient clinic setting when appropriate
National Reimbursement Benchmarks
Medicare’s mean rate of $95 sits well below BUCA’s average commercial mean of $331.9, indicating a substantial premium in commercial contracting versus the federal program for CPT 51720. The gap highlights how commercial payers can reimburse multiple times higher than Medicare, with BUCA’s mean approximately $236.9 higher than Medicare’s mean.
Dispersion varies across payers: Blue Cross Blue Shield shows the widest interquartile spread with P75−P25 = $200. -calculation yields $616.2 − $416.3 = $200.0, while Aetna and UnitedHealth Group exhibit tighter spreads of $59.0 and $85.7 respectively (Aetna: $95.8 − $39.0 = $56.8; UnitedHealth Group: $169.6 − $84.3 = $85.3). Cigna’s IQR is $84.5 ($160.8 − $73.6) and BUCA’s is $147.7 ($413.0 − $265.3). These differences reflect varying pricing consistency across payers.